Rafael-B | 8-K: FY2025 Q4 Revenue: USD 350 K

Revenue: As of FY2025 Q4, the actual value is USD 350 K.

EPS: As of FY2025 Q4, the actual value is USD -0.28.

EBIT: As of FY2025 Q4, the actual value is USD -13.06 M.

Net loss attributable to Rafael Holdings was $12.1 million, or $0.28 per share, for the fourth quarter of fiscal year 2025, compared to $4.5 million, or $0.19 per share, in the year-ago period. The increase in net loss is attributed to the consolidation of Cyclo Therapeutic’s expenses following the acquisition of Cyclo in March 2025 and the activity of Cornerstone and Day Three consolidated with Rafael Holdings during fiscal 2024.
For the full fiscal year 2025, the net loss was $30.5 million, or $1.04 per share, compared to $34.4 million, or $1.45 per share, in the year-ago period. The decrease in net loss is due to in-process R&D expense of $89.9 million related to the acquisition of Cornerstone netted with a $31.3 million recovery of receivables from Cornerstone in the year-ago period, $5.9 million in unrealized gains on the Company’s investment in Cyclo equity, and the inclusion of Cyclo following the acquisition in March 2025 and the activity of Cornerstone and Day Three consolidated with Rafael Holdings during fiscal 2024.

R&D expenses were $7.5 million for the three months ended July 31, 2025, compared to $1.5 million in the year-ago period. The increase is due to the inclusion of spending at Cyclo following the March 2025 acquisition and the activity of Cornerstone and Day Three consolidated with Rafael Holdings during fiscal 2024.
For the twelve months ended July 31, 2025, R&D expenses were $12.8 million, compared to $4.2 million in the year-ago period. The increase is due to the inclusion of spending at Cyclo following the March 2025 acquisition and the activity of Cornerstone and Day Three consolidated with Rafael Holdings during fiscal 2024.

G&A expenses were $5.5 million for the three months ended July 31, 2025, compared to $2.3 million in the year-ago period. The increase is due to the inclusion of expenses at Cyclo following the acquisition and the activity of Cornerstone and Day Three consolidated with Rafael Holdings during fiscal 2024.
For the twelve months ended July 31, 2025, G&A expenses were $13.8 million, compared to $8.9 million in the year-ago period. The increase is due to spending at Cyclo following the acquisition and the activity of Cornerstone and Day Three consolidated with Rafael Holdings during fiscal 2024.

As of July 31, 2025, cash and cash equivalents were $52.8 million. The Company closed a $25 million rights offering on June 4, 2025, which included the funding of the backstop commitment in the amount of $21.0 million by the Jonas family.

The company is focused on advancing the Trappsol® Cyclo™ program and investing in additional opportunities. The pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 is ongoing and could provide an important new treatment option for patients suffering from this rare and fatal genetic disease.